Dutch Colorectal Cancer Group

Quick facts

Phase 3 pipeline

• capecitabine-irinotecan · Oncology
  Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells.
• epirubicin+cisplatin+capecitabine
• FOLFOX/ FOLFIRI with bevacizumab · Oncology
  FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients.
• FOLFOX/ FOLFIRI with panitumumab · Oncology
  This combination uses chemotherapy (FOLFOX or FOLFIRI) to kill rapidly dividing cancer cells, while panitumumab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy efficacy.
• FOLFOXIRI with bevacizumab · Oncology
  FOLFOXIRI with bevacizumab combines three chemotherapy drugs (fluorouracil, oxaliplatin, and irinotecan) with an anti-angiogenic monoclonal antibody to kill colorectal cancer cells and block tumor blood vessel formation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dutch Colorectal Cancer Group portfolio CI brief
• Dutch Colorectal Cancer Group pipeline updates RSS